Advertisement
EVO vs PRGO
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EVO is a Buy and PRGO is a Hold.
EVO's RSI Oscillator ascending out of oversold territory
The RSI Oscillator for EVO moved out of oversold territory on October 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 39 similar instances when the indicator left oversold territory. In 30 of the 39 cases the stock moved higher. This puts the odds of a move higher at 77%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on EVO as a result. In 64 of 100 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.
The Moving Average Convergence Divergence (MACD) for EVO just turned positive on October 20, 2026. Looking at past instances where EVO's MACD turned positive, the stock continued to rise in 30 of 42 cases over the following month. The odds of a continued upward trend are 71%.
Following a +5.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where EVO advanced for three days, in 186 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
EVO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 59 cases where EVO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for EVO entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. EVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.746) is normal, around the industry mean (8.179). EVO's P/E Ratio (476.190) is considerably higher than the industry average of (-0.806). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.046) among similar stocks. P/S Ratio (0.695) is also within normal values, averaging (181.047).
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
PRGO in downward trend: price expected to drop as it breaks its higher Bollinger Band on October 15, 2026
PRGO broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 30 similar instances where the stock broke above the upper band. In 24 of the 30 cases the stock fell afterwards. This puts the odds of success at 80%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for PRGO moved out of overbought territory on October 19, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 20 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 67%.
The Momentum Indicator moved below the 0 level on October 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PRGO as a result. In 55 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 63%.
The Moving Average Convergence Divergence Histogram (MACD) for PRGO turned negative on October 26, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 27 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 66%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRGO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +4.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRGO advanced for three days, in 179 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Aroon Indicator entered an Uptrend today. In 125 of 204 cases where PRGO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 61%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.869) is normal, around the industry mean (8.029). P/E Ratio (-1.258) is within average values for comparable stocks, (-0.853). Projected Growth (PEG Ratio) (1.142) is also within normal values, averaging (2.152). Dividend Yield (0.074) settles around the average of (0.047) among similar stocks. P/S Ratio (0.454) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. PRGO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 89 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
EVO | PRGO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 15 | 81 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 92 Overvalued | 8 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 96 | 98 | |
PRICE GROWTH RATING 1..100 | 79 | 37 | |
P/E GROWTH RATING 1..100 | 1 | 89 | |
SEASONALITY SCORE 1..100 | 50 | 16 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PRGO's Valuation (8) in the Pharmaceuticals Other industry is significantly better than the same rating for EVO (92) in the null industry. This means that PRGO’s stock grew significantly faster than EVO’s over the last 12 months.
PRGO's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as EVO (100) in the null industry. This means that PRGO’s stock grew similarly to EVO’s over the last 12 months.
EVO's SMR Rating (96) in the null industry is in the same range as PRGO (98) in the Pharmaceuticals Other industry. This means that EVO’s stock grew similarly to PRGO’s over the last 12 months.
PRGO's Price Growth Rating (37) in the Pharmaceuticals Other industry is somewhat better than the same rating for EVO (79) in the null industry. This means that PRGO’s stock grew somewhat faster than EVO’s over the last 12 months.
EVO's P/E Growth Rating (1) in the null industry is significantly better than the same rating for PRGO (89) in the Pharmaceuticals Other industry. This means that EVO’s stock grew significantly faster than PRGO’s over the last 12 months.
| EVO | PRGO | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 77% | 2 days ago 67% |
| Stochastic ODDS (%) | 1 day ago 86% | 2 days ago 64% |
| Momentum ODDS (%) | 1 day ago 64% | 2 days ago 63% |
| MACD ODDS (%) | 1 day ago 71% | 2 days ago 66% |
| TrendWeek ODDS (%) | 1 day ago 79% | 2 days ago 66% |
| TrendMonth ODDS (%) | 1 day ago 77% | 2 days ago 63% |
| Advances ODDS (%) | 7 days ago 68% | 19 days ago 64% |
| Declines ODDS (%) | 2 days ago 80% | 2 days ago 67% |
| BollingerBands ODDS (%) | 1 day ago 73% | 2 days ago 80% |
| Aroon ODDS (%) | 1 day ago 77% | 2 days ago 61% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EVO’s FA Score shows that 1 FA rating(s) are green while PRGO’s FA Score has 1 green FA rating(s).
- EVO’s FA Score: 1 green, 4 red.
- PRGO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EVO’s TA Score shows that 5 TA indicator(s) are bullish while PRGO’s TA Score has 3 bullish TA indicator(s).
- EVO’s TA Score: 5 bullish, 3 bearish.
- PRGO’s TA Score: 3 bullish, 5 bearish.
Price Growth
EVO (@Pharmaceuticals: Generic) experienced а 0.00% price change this week, while PRGO (@Pharmaceuticals: Generic) price change was -0.44% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.43%. For the same industry, the average monthly price growth was -7.19%, and the average quarterly price growth was +2.27%.
Reported Earning Dates
EVO is expected to report earnings on Nov 05, 2026.
PRGO is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-1.43% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
PRGO and
Correlation & Price change
A.I.dvisor indicates that over the last year, PRGO has been loosely correlated with SUPN. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if PRGO jumps, then SUPN could also see price increases.
| Ticker / NAME | Correlation To PRGO | 1D Price Change % | ||
|---|---|---|---|---|
| PRGO | 100% | -0.32% | ||
| SUPN - PRGO | 49% Loosely correlated | -22.41% | ||
| ELAN - PRGO | 37% Loosely correlated | +1.95% | ||
| PBH - PRGO | 35% Loosely correlated | -0.38% | ||
| EVO - PRGO | 35% Loosely correlated | +1.97% | ||
| ALVO - PRGO | 34% Loosely correlated | +1.34% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SMIZ | 41.05 | 0.18 | +0.44% |
| Zacks Small/Mid Cap ETF (SMIZ) | |||
| QCOC | 24.32 | 0.08 | +0.33% |
| FT Vest Nasdaq-100 Conservative Buffer ETF - October (QCOC) | |||
| LIT | 60.10 | 0.05 | +0.08% |
| Global X Lithium & Battery Tech ETF (LIT) | |||
| ASEC | 49.46 | N/A | N/A |
| American Century Securitized Credit ETF (ASEC) | |||
| XPAV | 21.65 | N/A | N/A |
| Corgi U.S. Infrastructure 2x Daily ETF (XPAV) | |||